Microbiome Startup BiomX Raises $24 Million in Series A Round

May 15, 2017

|

CHICAGO (GenomeWeb) – BiomX, a startup focused on microbiome therapeutics via a proprietary microbiome modulation technology platform, said today that it has raised $24 million in Series A venture capital.

OrbiMed, Johnson & Johnson Innovation–JJDC, and Takeda Ventures led the round. Seventure Partners, MiraeAsset, the Japan-Israel Development Fund, and other unspecified European investors also participated, according to Ness Ziona, Israel-based BiomX.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Now You Can Read Them, Now You Can't

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

The Mouths of Heavy Drinkers Are Disgusting

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

For Health or For Fun?

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

This Week in Genome Research

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu